Sanofi snaps up Kadmon and its transplant drug Rezurock

Less than a month after Kadmon Pharma launched its first product – Rezurock for a complication of organ transplants – the New York company has agreed to be bought by Sanofi in a $1.9 billio

Shock as FDA rejects Mesoblast's Ryoncil in paediatric graft...

The FDA has rejected Mesoblast’s Ryoncil cell therapy for children with graft versus host disease, despite a recommendation to approve from a panel of expert advisers.

Kadmon preps filing for GVHD drug belumosudil after phase 3 ...

New York biotech Kadmon is on course to file for FDA approval of belumosudil for chronic graft versus host disease (GVHD) after it hit the mark in a pivotal trial.

Kiadis sheds half its staff as lead cell therapy bombs

Janssen/AbbVie drug approved in graft-versus-host disease

First use for Imbruvica outside blood cancer.

Imbruvica granted fourth Breakthrough status

The drug is also granted Orphan Drug Designation by the FDA.